Generic Name:
nintedanib
Project Status:
Complete
Therapeutic Area:
chronic fibrosing interstitial lung diseases
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Brand Name:
Ofev
Project Line:
Reimbursement Review
Project Number:
SR0654-000
Details
Manufacturer Requested Reimbursement Criteria1:
As per the Health Canada approved indication for progressive fibrosing-ILD (PF-ILD).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.